NAD+ supplementation may promote tumor-killing by tumor-infiltrated T cells after anti-PD1 immune checkpoint inhibitor treatment or adoptive chimeric antigen receptor (CAR) T cells through rescuing defective TUB-mediated NAMPT transcription[166]. The gene discussed is TUB; the disease is neoplasm.